Cardiologist. Inherited Cardiovascular Diseases. Cardiopatías y Aortopatías Familiares. @HUnivValdecilla H.U. Marqués de Valdecilla. Santander. 🇪🇸
Joined January 2020
- Tweets 467
- Following 111
- Followers 214
- Likes 1,174
13 Photos and videos
Luis Ruiz Guerrero retweeted
May 5
ACACIA-HCM trial topline results - aficamten in nHCM. Incredibly proud and thankful to our patients and team for their commitment and hard work. This represents the first effective treatment for patients with nHCM. looking forward to seeing the full results.
#CardioTwitter
4
31
75
5,277
Luis Ruiz Guerrero retweeted
29 Dec 2025
Danicamtiv enhanced cardiac myosin function in vitro and was generally well tolerated in #DCM. Echo findings suggest improved contractility, with strongest responses in #MYH7 and TTN cohorts jacc.org/doi/10.1016/j.jacc.… #JACC #cvDCM
1
10
40
5,166
Luis Ruiz Guerrero retweeted
8 Apr 2025
Early-onset AF, especially without risk factors --> myocardial disease --> genetic evaluation
medrxiv.org/content/10.1101/…
#CardioTwitter
11
21
1,851
Luis Ruiz Guerrero retweeted
8 Apr 2025
RBM20 cardiomyopathy carries a more significant burden at a younger age, and an accelerated course compared to TTN cardiomyopathy
pmc.ncbi.nlm.nih.gov/article…
#CardioTwitter
5
17
1,398
Luis Ruiz Guerrero retweeted
3 Apr 2025
A deep dive into the mechanisms of ALPK3 associated HCM
#CardioTwitter
nature.com/articles/s41598-0…
1
7
17
1,640
Luis Ruiz Guerrero retweeted
1 Apr 2025
📣New Consensus is out in #Europace
#EHRA2025
💊The diagnostic role of pharmacological provocation testing in cardiac electrophysiology💥
🔗 doi.org/10.1093/europace/eua…
@GiulioConte9 @Dominik_Linz @FraSantoroMD @AndyZhangMD @DavideMei93 @marcovitoloMD @LuigiDiBiaseMD
30
67
7,337
Luis Ruiz Guerrero retweeted
30 Mar 2025
Limiting fluid intake may have no benefit for patients with #HeartFailure, according to findings from the FRESH-UP study presented during a Late-Breaking Clinical Trial session at #ACC25.
Check out the key findings ➡️ bit.ly/3DYGHEl
31
97
10,574
Luis Ruiz Guerrero retweeted
24 Mar 2025
Late Gadolinium Enhancement in Early Repolarization Syndrome
heartrhythmjournal.com/artic…
11
30
3,023
Luis Ruiz Guerrero retweeted
22 Mar 2025
📅 The A Coruña Hypertrophic Cardiomyopathy Congress is Back!
🗓 September 18-19, 2025
🔬 Experts from 🇦🇷 🇦🇺 🇩🇪 🇪🇸 🇫🇷 🇬🇧 🇮🇹 🇳🇱 🇵🇹 🇺🇸 @seccCFyGenetCV @secardiologia
🔗 hypertrophiccardiomyopathyac…
1
22
44
4,185
Luis Ruiz Guerrero retweeted
10 Dec 2024
Low penetrance sarcomere variants (LowSVs) contribute to mild HCM alone but increase severity with high-risk variants. @neallakdawala @drjamesware @tikuowens @jodieingles27 @S2beri @sday_hcm @SeanLZheng @AdamHelmsMD ahajournals.org/doi/abs/10.1…
1
16
35
8,819
Luis Ruiz Guerrero retweeted
11 Mar 2025
🧬 24% of patients with heritable arrhythmias & cardiomyopathies carry a disease-causing variant—but only 8% see changes in clinical management. How do we close the gap? Read the study: jacc.org/doi/10.1016/j.jacc.…
#JACC #Genetics #CardioScience #PrecisionMedicine #cvGenetics
33
72
9,895
Luis Ruiz Guerrero retweeted
7 Mar 2025
Cardiopulmonary exercise testing (CPET) has a unique role in the assessment of cardiopulmonary disease. @BrazileTiffany and colleagues review key CPET variables, protocols and clinical indications. eviden.cc/4aC6uOt
ALT A visual representation of cardiopulmonary exercise testing applications.
1
109
286
45,711
Heart failure with preserved ejection fraction is noted for symptoms of heart failure, LVEF of at least 50%, and cardiac or structural abnormalities. Treatment includes diuretics and SGLT2 inhibitors. Learn more: nej.md/4h41K6k
ALT A diagram of a pragmatic approach to the diagnosis of heart failure with preserved ejection fraction.
91
252
29,367
Luis Ruiz Guerrero retweeted
8 Jan 2025
🔬New in @JACCJournals: HCM diagnosis criteria show unexpected demographic bias. Study of 50,000 hearts reveals current thresholds create 8:1 male-female ratio
Proposing demographic-adjusted thresholds to improve diagnosis🫀
authors.elsevier.com/a/1kPE5…
@UCL_ICS @NHSBartsHealth
5
27
58
6,803
Luis Ruiz Guerrero retweeted
31 Dec 2024
I am very happy to end 2024 with the publication of our study "Validation of a hand-held ultrasound device in the evaluation of aortic stenosis".
Thanks to all the collaborators @raquelpbarquin #AdrianMargarida @HUnivValdecilla @IDIVALdecilla
link.springer.com/10.1007/s1…
4
15
407
Luis Ruiz Guerrero retweeted
26 Dec 2024
This is nice work on an important question in EP. I have an idea about a subgroup. Mandrola theory of de novo AFlutter. If it occurs in pt w prior heart surgery, CTI likely enough. If no prior surgery, CTI PVI better. #epeeps
LOE 👆= opinion. #EPeeps
26 Dec 2024
Should we isolate the pulmonary veins in all patients with atrial flutter? Does PVI replace the need for cavitricuspid isthmus isolation? Provocative findings in systematic led by Daniel Gomes. Great collaboration @SergeBoveda , @DhirajGuptaBHRS , et al. #Afib #atrialfibrillation
1
4
28
8,426
Luis Ruiz Guerrero retweeted
23 Dec 2024
As promised, here is a slew of content ...re the PLATO trial of ticagrelor vs clopidogrel in patients with ACS
This all occurred in 2009, early in my critical appraisal learning.
Revisiting PLATO controversy is super important--both clinically and epistemologically
2
11
64
13,646
Luis Ruiz Guerrero retweeted
13 Dec 2024
🗝️ Collecting a detailed family history and pertinent clinical data for patients with cardiomyopathies is needed to guide potential use of genetic testing.
Read more key points on genetic testing for cardiomyopathies ➡️ bit.ly/4fho5vK #HeartFailure
1
6
15
2,879
Luis Ruiz Guerrero retweeted
11 Dec 2024
2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis: A Report of the American College of Cardiology Solution Set Oversight Committee | Journal of the American College of Cardiology jacc.org/doi/10.1016/j.jacc.…
4
5
482
Luis Ruiz Guerrero retweeted
9 Dec 2024
How to include mDNA in HCM genetic panels? humgenomics.biomedcentral.co…
2
3
308